Vector Labs Ab04181-10.3 Anti-Integrin alpha-4/beta-7 [Vedolizumab (LDP-02)], Human IgG1, Fc Silent™, kappa (100 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: Vedolizumab (LDP-02)
Heavy Chain Modification: Fc Silent™
Synonyms: Integrin α4β7; CD49D; ITGA4:ITGB7; Peyer patches-specific homing receptor LPAM-1; ITGA4; Integrin alpha-4; CD49 antigen-like family member D; Integrin alpha-IV; VLA-4 subunit alpha; ITGB7; Integrin beta-7; Gut homing receptor beta subunit; ACT-1; LDP02; MLN-02; MLN0002; MLN02; ENTYVIO
Amount: 100 μg
Application Codes Clone: FC; therapeutic
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG1
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Specificity Statement: This antibody is specific for human α4β7 integrin and does not cross react with alpha(4)beta(1) and alpha(E)beta(7) integrins. This antibody does not bind majority of memory CD4(+) T lymphocytes (60%), neutrophils, and most monocytes. It binds to a subset (approximately 25%) of human peripheral blood memory CD4(+) T lymphocytes that include gut-homing interleukin 17 T-helper lymphocytes. It also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels
Application Notes: The binding characterization of this antibody for human alpha 4 beta 7 integrin was done using flow cytometry on Hut-78 cells (US7147851B1). In a double-blind, placebo-controlled trial this antibody was more effective than placebo for the induction of clinical and endoscopic remission in patients with active ulcerative colitis (PMID: 15958805). In a phase II clinical trial, it was reported that this antibody is well tolerated in patients with active Crohn's disease and therapy with this antibody had a dose-dependent beneficial effect on clinical remission (PMID: 18829392). This antibody exclusively binds alpha4 beta7 integrin and modulates inflammation in the gastrointestinal tract without inducing the systemic immunosuppression. This antibody binds memory CD4(+) T and B lymphocytes with sub nanomolar potency (EC(50) = 0.3-0.4 nM). This antibody inhibits adhesion of alpha(4)beta(7)-expressing cells to mucosal addressing cell adhesion molecule 1 (median inhibition concentration [IC(50)] = 0.02-0.06 microg/ml) and fibronectin (IC(50) = 0.02 microg/ml), but not vascular cell adhesion molecule 1. The pharmacologic properties of vedolizumab, in conjunction with the gastrointestinal tropism of alpha(4)beta(7) integrin function, make it a suitable for treatment of patients with inflammatory bowel diseases (PMID: 19509315).

Product Class:	Purified
Clone ID:	Vedolizumab (LDP-02)
Heavy Chain Modification:	Fc Silent™
Synonyms:	Integrin α4β7; CD49D; ITGA4:ITGB7; Peyer patches-specific homing receptor LPAM-1; ITGA4; Integrin alpha-4; CD49 antigen-like family member D; Integrin alpha-IV; VLA-4 subunit alpha; ITGB7; Integrin beta-7; Gut homing receptor beta subunit; ACT-1; LDP02; MLN-02; MLN0002; MLN02; ENTYVIO
Amount:	100 μg
Application Codes Clone:	FC; therapeutic
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG1
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Specificity Statement:	This antibody is specific for human α4β7 integrin and does not cross react with alpha(4)beta(1) and alpha(E)beta(7) integrins. This antibody does not bind majority of memory CD4(+) T lymphocytes (60%), neutrophils, and most monocytes. It binds to a subset (approximately 25%) of human peripheral blood memory CD4(+) T lymphocytes that include gut-homing interleukin 17 T-helper lymphocytes. It also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels
Application Notes:	The binding characterization of this antibody for human alpha 4 beta 7 integrin was done using flow cytometry on Hut-78 cells (US7147851B1). In a double-blind, placebo-controlled trial this antibody was more effective than placebo for the induction of clinical and endoscopic remission in patients with active ulcerative colitis (PMID: 15958805). In a phase II clinical trial, it was reported that this antibody is well tolerated in patients with active Crohn's disease and therapy with this antibody had a dose-dependent beneficial effect on clinical remission (PMID: 18829392). This antibody exclusively binds alpha4 beta7 integrin and modulates inflammation in the gastrointestinal tract without inducing the systemic immunosuppression. This antibody binds memory CD4(+) T and B lymphocytes with sub nanomolar potency (EC(50) = 0.3-0.4 nM). This antibody inhibits adhesion of alpha(4)beta(7)-expressing cells to mucosal addressing cell adhesion molecule 1 (median inhibition concentration [IC(50)] = 0.02-0.06 microg/ml) and fibronectin (IC(50) = 0.02 microg/ml), but not vascular cell adhesion molecule 1. The pharmacologic properties of vedolizumab, in conjunction with the gastrointestinal tropism of alpha(4)beta(7) integrin function, make it a suitable for treatment of patients with inflammatory bowel diseases (PMID: 19509315).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews